Clinical trial· 2023
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.
Lancet (London, England)
Back to all molecules
Human researchNot FDA-approved
CagriSema
Investigational semaglutide–cagrilintide combination
Also indexed as: Cagrilintide + Semaglutide
What this evidence does not tell us
The cited phase 2 trial is in type 2 diabetes. Outcomes apply to that studied combination and population, not arbitrary mixtures.
Terms on this page
Unfamiliar word? Open this panel for simple explanations, right here.
8 glossary terms used in this profile
Terms on this page
Unfamiliar word? Open this panel for simple explanations, right here.
8 glossary terms used in this profile
Select a word to see its meaning. You can keep more than one definition open.
Definitions explain the words—not whether a molecule works or is safe. Research education only, not medical advice.
Overview
CagriSema is the development name for a combination of cagrilintide and semaglutide studied in metabolic clinical research. It is a combination program, not a single naturally occurring molecule.
Mechanism of action
GLP-1 / amylin
Combines GLP-1 receptor agonism (semaglutide) with amylin-receptor signaling (cagrilintide), investigated for complementary appetite and glucose effects.
A biological pathway describes a proposed or observed interaction—not necessarily a demonstrated health outcome.
Decode the terminology in our glossaryScientific evidence
How strong is the evidence?
Human evidence is still developing
- Limited evidence
- Early research
- Human researchCurrent category
- Human outcomes
Studies in people exist, but the findings may be small, narrow, mixed or still need confirmation. A hormone or cell marker is not necessarily a health benefit.
For this research: The cited phase 2 trial is in type 2 diabetes. Outcomes apply to that studied combination and population, not arbitrary mixtures.
An editorial guide—not a validated score, a percentage, a safety rating or an approval badge. Regulatory status is separate. More research does not mean fewer risks.
Cell studies
Mechanistic laboratory evidence is not separately assessed in this selected-source summary; see references and their study types.
Animal experiments
Animal evidence is not separately assessed here. Findings in animals must not be interpreted as demonstrated human benefit.
Human observational studies
Associations, biomarker studies and anecdotes cannot establish treatment causality; no observational result is used here to infer clinical effectiveness.
Human clinical trials
The cited phase 2 randomized trial studied co-administered cagrilintide and semaglutide in adults with type 2 diabetes.
Regulatory evidence
No FDA-approved finished drug for this molecule is identified in this edition. Investigational use, published research or compounding does not establish FDA approval.
Potential research applications
Combined GLP-1 and amylin signaling for metabolic outcomes.
These describe scientific questions, not prescribing recommendations. A research grouping does not establish combination safety or clinical effectiveness.
Explore research by health goalSafety considerations
Gastrointestinal adverse effects and tolerability are important study endpoints. Semaglutide-related risks remain relevant; interactions and eligibility require trial-specific assessment.
This is not an exhaustive safety or contraindication list. An absence of reported harm is not proof of safety. Pregnancy, breastfeeding, cancer history, endocrine disease and concurrent medicines can materially change risk. Unregulated preparations add identity, contamination and sterility risks.
Regulatory status · United States
Not FDA-approved
No FDA-approved finished drug for this molecule is identified in this edition. Investigational use, published research or compounding does not establish FDA approval.
Regulatory status and evidence strength are different. A nomination for compounding, a clinical-trial registration or a “research use only” label is not approval. International rules vary; consult the current regulator and product label.
Selected literature & source transparency
Matched bibliographic records confirm a publication’s identity, not the validity of every claim. Selected sources are not a systematic literature review.
Continue your own source search
These open search results, not additional verified citations. Trial registration is not evidence that a treatment works.
Three questions worth bringing to your clinician
- Which human outcomes—not just biomarkers—support this claim?
- What established options address my actual health concern?
- What do my medical history and current medicines change about the risks?
Beyond the library
Turn better questions into a thoughtful conversation.
Explore our broader health optimization approach. A library entry does not mean a molecule is offered, prescribed, or appropriate for you.
Request an Optimization Consultation
Continue to our existing activation & intake page.